Skip to main content
SpringerLink
Log in

Positronen-Emissionstomographie bei Phäochromozytomen und Paragangliomen

  • Chapter
  • First Online:
Nuklearmedizin bei endokrinen Erkrankungen

  • 45 Accesses

Zusammenfassung

PET/CT hat aufgrund verbesserter Geräteerfassungsmerkmale die diagnostische Bewertung von Phäochromozytomen und Paragangliomen verbessert. PET-Radiotracer für diese Tumoren bewerten häufig die Expression von Somatostatinrezeptoren, Aminosäuretransportsystemen oder den Glukosestoffwechsel. Die Sensitivität ist im Vergleich zu MIBG verbessert, einschließlich bei Tumoren mit SDHx-Genmutationen. Falsch positive Ergebnisse können Läsionen von anderen Tumoren, Meningiomen, entzündlichen Krankheiten oder physiologischer Pankreas-Aufnahme einschließen. Falsch negative Ergebnisse können aufgrund von Harn-Radiotracer-Ausscheidung oder der Verwendung von kalten Somatostatinanaloga zur Tumorkontrolle auftreten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 34.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 44.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Kroiss AS. Current status of functional imaging in neuroblastoma, pheochromocytoma, and paraganglioma disease. Wien Med Wochenschr. 2019;169(1–2):25–32.

    Article  PubMed  Google Scholar 

  2. Sbardella E, Grossman AB. Pheochromocytoma: an approach to diagnosis. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101346.

    Article  CAS  PubMed  Google Scholar 

  3. Crona J, Taïeb D, Pacak K. New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr Rev. 2017;38(6):489–515.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14(2):108–19.

    Article  CAS  PubMed  Google Scholar 

  5. Ryder SJ, Love AJ, Duncan EL, Pattison DA. PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics era. Clin Endocrinol (Oxf). 2021;95(1):13–28.

    Article  PubMed  Google Scholar 

  6. Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46(10):2112–37.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Timmers HJLM, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104(9):700–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Taïeb D, Neumann H, Rubello D, Al-Nahhas A, Guillet B, Hindié E. Modern nuclear imaging for paragangliomas: beyond SPECT. J Nucl Med. 2012;53(2):264–74.

    Article  PubMed  Google Scholar 

  9. Taïeb D, Rubello D, Al-Nahhas A, Calzada M, Marzola MC, Hindié E. Modern PET imaging for paragangliomas: relation to genetic mutations. Eur J Surg Oncol. 2011;37(8):662–8.

    Article  PubMed  Google Scholar 

  10. Havekes B, King K, Lai EW, Romijn JA, Corssmit EPM, Pacak K. New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2010;72(2):137–45.

    Article  CAS  PubMed  Google Scholar 

  11. Jain A, Baracco R, Kapur G. Pheochromocytoma and paraganglioma – an update on diagnosis, evaluation, and management. Pediatr Nephrol. 2020;35(4):581–94.

    Article  PubMed  Google Scholar 

  12. Mazzaglia PJ. Hereditary pheochromocytoma and paraganglioma. J Surg Oncol. 2012;106(5):580–5.

    Article  CAS  PubMed  Google Scholar 

  13. Taïeb D, Pacak K. Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. Cell Tissue Res. 2018;372(2):393–401.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Heesterman BL, de Pont LMH, van der Mey AG, Bayley J-P, Corssmit EP, Hes FJ, et al. Clinical progression and metachronous paragangliomas in a large cohort of SDHD germline variant carriers. Eur J Hum Genet EJHG. 2018;26(9):1339–47.

    Article  PubMed  Google Scholar 

  15. Lepoutre-Lussey C, Caramella C, Bidault F, Déandreis D, Berdelou A, Al Ghuzlan A, et al. Screening in asymptomatic SDHx mutation carriers: added value of 18F-FDG PET/CT at initial diagnosis and 1-year follow-up. Eur J Nucl Med Mol Imaging. 2015;42(6):868–76.

    Article  CAS  PubMed  Google Scholar 

  16. Daniel E, Jones R, Bull M, Newell-Price J. Rapid-sequence MRI for long-term surveillance for paraganglioma and phaeochromocytoma in patients with succinate dehydrogenase mutations. Eur J Endocrinol. 2016;175(6):561–70.

    Article  CAS  PubMed  Google Scholar 

  17. Waguespack SG, Rich T, Grubbs E, Ying AK, Perrier ND, Ayala-Ramirez M, et al. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2010;95(5):2023–37.

    Article  CAS  PubMed  Google Scholar 

  18. Carrasquillo JA, Chen CC, Jha A, Ling A, Lin FI, Pryma DA, et al. Imaging of pheochromocytoma and paraganglioma. J Nucl Med. 2021;62(8):1033–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Naji M, Al-Nahhas A. 68Ga-labelled peptides in the management of neuroectodermal tumours. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S61–7.

    Google Scholar 

  20. Hofman MS, Lau WFE, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35(2):500–16.

    Article  PubMed  Google Scholar 

  21. Sharma P, Thakar A, Suman KCS, Dhull VS, Singh H, Naswa N, et al. 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma. J Nucl Med. 2013;54(6):841–7.

    Article  CAS  PubMed  Google Scholar 

  22. Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13(4):769–75.

    Article  PubMed  Google Scholar 

  23. Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, Url C, et al. (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging. 2015;42(1):33–41.

    Article  PubMed  Google Scholar 

  24. Sharma P, Mukherjee A, Karunanithi S, Naswa N, Kumar R, Ammini AC, et al. Accuracy of 68Ga DOTANOC PET/CT imaging in patients with multiple endocrine neoplasia syndromes. Clin Nucl Med. 2015;40(7):e351–6.

    Article  PubMed  Google Scholar 

  25. Chang CA, Pattison DA, Tothill RW, Kong G, Akhurst TJ, Hicks RJ, et al. (68)Ga-DOTATATE and (18)F-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging. 2016;16(1):22.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Kan Y, Zhang S, Wang W, Liu J, Yang J, Wang Z. 68Ga-somatostatin receptor analogs and 18F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis. Acta Radiol. 2018;59(12):1466–74.

    Article  PubMed  Google Scholar 

  27. Gild ML, Naik N, Hoang J, Hsiao E, McGrath RT, Sywak M, et al. Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clin Endocrinol (Oxf). 2018;89(2):139–47.

    Article  CAS  PubMed  Google Scholar 

  28. Castellucci P, Pou Ucha J, Fuccio C, Rubello D, Ambrosini V, Montini GC, et al. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med. 2011;52(6):886–90.

    Article  PubMed  Google Scholar 

  29. Zampetti B, Attanasio R, Boniardi M, Cozzi R. False positive of 68Ga-DOTATATE PET-CT in a paraganglioma. Endocr Metab Immune Disord Drug Targets. 2021;21(7):1352–5.

    Article  CAS  PubMed  Google Scholar 

  30. Taïeb D, Jha A, Guerin C, Pang Y, Adams KT, Chen CC, et al. 18F-FDOPA PET/CT imaging of MAX-related pheochromocytoma. J Clin Endocrinol Metab. 2018;103(4):1574–82.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging. 2012;39(7):1144–53.

    Article  PubMed  Google Scholar 

  32. Fiebrich H-B, Brouwers AH, Kerstens MN, Pijl MEJ, Kema IP, de Jong JR, et al. 6-[F-18]Fluoro-l-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 2009;94(10):3922–30.

    Article  CAS  PubMed  Google Scholar 

  33. Timmers HJLM, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-l-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):4757–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-Fluoro-l-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95(6):2800–10.

    Article  CAS  PubMed  Google Scholar 

  35. King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, Patronas N, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-d-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96(9):2779–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Taïeb D, Tessonnier L, Sebag F, Niccoli-Sire P, Morange I, Colavolpe C, et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf). 2008;69(4):580–6.

    Article  PubMed  Google Scholar 

  37. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, et al. Pheochromocytomas: detection with 18F DOPA whole body PET – initial results. Radiology. 2002;222(2):507–12.

    Article  PubMed  Google Scholar 

  38. Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, et al. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009;50(4):513–9.

    Article  PubMed  Google Scholar 

  39. Taïeb D, Sebag F, Barlier A, Tessonnier L, Palazzo FF, Morange I, et al. 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med. 2009;50(5):711–7.

    Article  PubMed  Google Scholar 

  40. Guerin C, Pattou F, Brunaud L, Lifante J-C, Mirallié E, Haissaguerre M, et al. Performance of 18F-FDG PET/CT in the characterization of adrenal masses in noncancer patients: a prospective study. J Clin Endocrinol Metab. 2017;102(7):2465–72.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Physician and Researcher, São Paulo State Cancer Institute–University of São Paulo Medical School (HCFMUSP), São Paulo, Brazil

    George Barberio Coura-Filho

  2. DIMEN Medicina Nuclear, São Paulo, Brazil

    Mayara Torres Silva de Oliveira

  3. DIMEN Medicina Nuclear, São Paulo, Brazil

    Ana Luiza Morais de Campos

Authors
  1. George Barberio Coura-Filho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mayara Torres Silva de Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Luiza Morais de Campos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George Barberio Coura-Filho .

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Der/die Autor(en), exklusiv lizenziert an Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Coura-Filho, G.B., Torres Silva de Oliveira, M., Morais de Campos, A.L. (2024). Positronen-Emissionstomographie bei Phäochromozytomen und Paragangliomen. In: Nuklearmedizin bei endokrinen Erkrankungen. Springer, Cham. https://doi.org/10.1007/978-3-031-47988-5_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-47988-5_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-47987-8

  • Online ISBN: 978-3-031-47988-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation